High-Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer's Disease: Drug Profile and Clinical Guidelines

Efficacy and Safety of Donepezil 23 mg versus Donepezil 10 mg for Moderate-to-Severe Alzheimer’s Disease: A Subgroup Analysis in Patients Already Taking or Not Taking Concomitant Memantine

(2012) Rachelle S. Doody et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease

(2012) Robert Howard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predictors of costs of care in Alzheimer’s disease: A multinational sample of 1222 patients

(2011) Anders Gustavsson et al.   Alzheimers & Dementia

Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)

(2011) Paul S. Aisen et al.   Archives of Medical Science

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

(2011) Martin Farlow et al.   BMC Neurology

Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology

(2011) Marwan Sabbagh et al.   BMC Neurology

Changes in Nursing Burden Following Memantine for Agitation and Aggression in Long-Term Care Residents with Moderate to Severe Alzheimerʼs Disease

(2011) Nathan Herrmann et al.   CNS DRUGS

Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease

(2011) Steven H Ferris et al.   Alzheimers Research & Therapy

Caregiver Burden in Alzheimer Disease: Cross-Sectional and Longitudinal Patient Correlates

(2010) Somaia Mohamed et al.   AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

(2010) Martin R. Farlow et al.   CLINICAL THERAPEUTICS

The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimerʼs Disease

(2010) Jaclyn Cappell et al.   CNS DRUGS

Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer's disease

(2010) Niklas Bergvall et al.   INTERNATIONAL PSYCHOGERIATRICS

Alzheimer's failure raises questions about disease-modifying strategies

(2010) Andy Extance   NATURE REVIEWS DRUG DISCOVERY

Safety and Tolerability of Donepezil at Doses up to 20 mg/day

(2009) Rachelle S Doody et al.   DRUGS & AGING

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled Trial

(2009) Robert C. Green   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Predictors of Nursing Home Admission for Persons with Dementia

(2009) Joseph E. Gaugler et al.   MEDICAL CARE

Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis

(2007) S. Gauthier et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY